Clearmind Medicine Announces Notice of Patent Publication for Depression Treatment

The notice was received by the China National Intellectual Property Administration

Vancouver, Canada, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the “Company”), a clinical-stage biotech company focused on discovery and development of novel neuroplastogen-derived therapeutics to solve major under-treated health problems, today announced notice of publication by the China National Intellectual Property Administration, referring to the Company’s proprietary non hallucinogenic compound, 5-methoxy-2-aminoindane (MEAI), for the treatment of depression.

Read more at globenewswire.com